GLP-1 MARKET ANALYSIS

Date: March 2025
Author: Healthcare Research Team

MARKET SIZE:
- 2024: $35 billion
- 2030E: $150 billion (CAGR 25%)

KEY PLAYERS:
1. Novo Nordisk (Ozempic, Wegovy)
   - Market share: 55%
   - Supply: Constrained
   
2. Eli Lilly (Mounjaro, Zepbound)
   - Market share: 35%
   - Supply: Improving

3. Emerging Players
   - Amgen (oral GLP-1)
   - Viking Therapeutics
   - Structure Therapeutics

INVESTMENT IMPLICATIONS:
- Prefer LLY over NVO (supply, pipeline)
- Watch for oral formulations
- CDMOs benefiting (Catalent, Lonza)

RISKS:
- Pricing pressure from payers
- Safety signals (thyroid cancer)
- Competition intensifying
